First-in-human trial of the post-exposure tuberculosis vaccine H56: IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

Vaccine

Volumn 33, Issue 33, 2015, Pages 4130-4140

  Luabeya, Angelique Kany Kany ^a   Kagina, Benjamin M N ^a,b   Tameris, Michele D ^a   Geldenhuys, Hennie ^a   Hoff, Soren T ^c   Shi, Zhongkai ^d   Kromann, Ingrid ^c   Hatherill, Mark ^a   Mahomed, Hassan ^a,e   Hanekom, Willem A ^a   Andersen, Peter ^c   Scriba, Thomas J ^a   Schoeman, Elisma ^a   Krohn, Colleen ^a   Day, Cheryl L ^a,f,g   Africa, Hadn ^a   Makhethe, Lebohang ^a   Smit, Erica ^a   Brown, Yolande ^a   Suliman, Sara ^a   Hughes, E Jane ^a   Bang, Peter ^c   Snowden, Margaret A ^d   McClain, Bruce ^d   Hussey, Gregory D ^a,b   more..

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c STATENS SERUM INSTITUT   (Denmark)

^d AERAS   (United States)

^e WESTERN CAPE DEPARTMENT OF AGRICULTURE   (South Africa)

^f EMORY UNIVERSITY   (United States)

^g EMORY UNIVERSITY   (United States)

Author keywords

Clinical trial; H56; Latent; Tuberculosis; Vaccine

Indexed keywords

ALANINE AMINOTRANSFERASE; BCG VACCINE; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; H56:IC31 VACCINE; HEMOGLOBIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; RECOMBINANT VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACYLTRANSFERASE; ANTIGEN 85B, MYCOBACTERIUM TUBERCULOSIS; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CYTOKINE; DRUG COMBINATION; ESAT-6 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; IC31 ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; OLIGOPEPTIDE;

ADULT; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTHRALGIA; ARTICLE; ASTHMA; BACKACHE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CHILL; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; ENTEROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; FIRST IN HUMAN STUDY; FLU LIKE SYNDROME; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; HYPESTHESIA; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INJECTION SITE WARMTH; JOINT STIFFNESS; LIMB PAIN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MEMORY T LYMPHOCYTE; MUSCULOSKELETAL PAIN; MYALGIA; MYCOBACTERIUM TUBERCULOSIS; PHASE 1 CLINICAL TRIAL; PHENOTYPIC VARIATION; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RHINITIS; SIDE EFFECT; SINUSITIS; SKIN REDNESS; STAINING; T LYMPHOCYTE; TUBERCULOSIS; ULCER; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; ADOLESCENT; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; NORMAL HUMAN; PATHOLOGY; PROCEDURES; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; YOUNG ADULT;

ACYLTRANSFERASES; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DRUG COMBINATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OLIGODEOXYRIBONUCLEOTIDES; OLIGOPEPTIDES; POST-EXPOSURE PROPHYLAXIS; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS VACCINES; YOUNG ADULT;

EID: 84952639195     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.051     Document Type: Article

References (45)

1. WHO Global tuberculosis control: surveillance, planning, financing 2009, WHO.
2. WHO World Health Organization report: global tuberculosis control. Geneva, Switzerland 2011, WHO Global Tuberculosis Control Report 2011.
3. Dye C., Glaziou P., Floyd K., Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health 2013, 34:271-286.
4. Abu-Raddad L.J., Sabatelli L., Achterberg J.T., Sugimoto J.D., Longini I.M., Dye C., et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A 2009, 106:13980-13985.
5. Aagaard C., Hoang T., Dietrich J., Cardona P.J., Izzo A., Dolganov G., et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011, 17:189-194.
6. Schellack C., Prinz K., Egyed A., Fritz J.H., Wittmann B., Ginzler M., et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 2006, 24:5461-5472.
7. Agger E.M., Rosenkrands I., Olsen A.W., Hatch G., Williams A., Kritsch C., et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 2006, 24:5452-5460.
8. Skeiky Y.A., Dietrich J., Lasco T.M., Stagliano K., Dheenadhayalan V., Goetz M.A., et al. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine 2010, 28:1084-1093.
9. van Dissel J.T., Arend S.M., Prins C., Bang P., Tingskov P.N., Lingnau K., et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010, 28:3571-3581.
10. Rohde K.H., Veiga D.F., Caldwell S., Balazsi G., Russell D.G. Linking the transcriptional profiles and the physiological states of Mycobacterium tuberculosis during an extended intracellular infection. PLoS Pathog 2012, 8:e1002769.
11. Wilkinson R.J., DesJardin L.E., Islam N., Gibson B.M., Kanost R.A., Wilkinson K.A., et al. An increase in expression of a Mycobacterium tuberculosis mycolyl transferase gene (fbpB) occurs early after infection of human monocytes. Mol Microbiol 2001, 39:813-821.
12. Ronning D.R., Klabunde T., Besra G.S., Vissa V.D., Belisle J.T., Sacchettini J.C. Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. Nat Struct Biol 2000, 7:141-146.
13. Ganguly N., Giang P.H., Gupta C., Basu S.K., Siddiqui I., Salunke D.M., et al. Mycobacterium tuberculosis secretory proteins CFP-10, ESAT-6 and the CFP10:ESAT6 complex inhibit lipopolysaccharide-induced NF-kappaB transactivation by downregulation of reactive oxidative species (ROS) production. Immunol Cell Biol 2008, 86:98-106.
14. Lin P.L., Dietrich J., Tan E., Abalos R.M., Burgos J., Bigbee C., et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 2012, 122:303-314.
15. Copin R., Coscolla M., Efstathiadis E., Gagneux S., Ernst J.D. Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG). Vaccine 2014, 32:5998-6004.
16. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999, 284:1520-1523.
17. Trajkovic V., Natarajan K., Sharma P. Immunomodulatory action of mycobacterial secretory proteins. Microbes Infect 2004, 6:513-519.
18. Mustafa A.S., Shaban F.A., Abal A.T., Al-Attiyah R., Wiker H.G., Lundin K.E., et al. Identification and HLA restriction of naturally derived Th1-cell epitopes from the secreted Mycobacterium tuberculosis antigen 85B recognized by antigen-specific human CD4(+) T-cell lines. Infect Immun 2000, 68:3933-3940.
19. Brodin P., Majlessi L., Marsollier L., de Jonge M.I., Bottai D., Demangel C., et al. Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. Infect Immun 2006, 74:88-98.
20. Mustafa A.S., Oftung F., Amoudy H.A., Madi N.M., Abal A.T., Shaban F., et al. Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines. Clin Infect Dis 2000, 30(Suppl. 3):S201-S205.
21. Betts J.C., Lukey P.T., Robb L.C., McAdam R.A., Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002, 43:717-731.
22. Govender L., Abel B., Hughes E.J., Scriba T.J., Kagina B.M., de Kock M., et al. Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine 2010, 29:51-57.
23. Zheng J., Liu L., Wei C., Leng W., Yang J., Li W., et al. A comprehensive proteomic analysis of Mycobacterium bovis bacillus Calmette-Guerin using high resolution Fourier transform mass spectrometry. J Proteomics 2012, 77:357-371.
24. Houghton J., Cortes T., Schubert O., Rose G., Rodgers A., De Ste Croix M., et al. A small RNA encoded in the Rv2660c locus of Mycobacterium tuberculosis is induced during starvation and infection. PLOS ONE 2013, 8:e80047.
25. Voskuil M.I., Visconti K.C., Schoolnik G.K. Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis (Edinb) 2004, 84:218-227.
26. Fourie P.B. BCG vaccination and the EPI. S Afr Med J 1987, 72:323-326.
27. Forbes E.K., Sander C., Ronan E.O., McShane H., Hill A.V., Beverley P.C., et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008, 181:4955-4964.
28. Lindenstrom T., Knudsen N.P., Agger E.M., Andersen P. Control of chronic Mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells. J Immunol 2013, 190:6311-6319.
29. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
30. Mahnke Y.D., Brodie T.M., Sallusto F., Roederer M., Lugli E. The who's who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol 2013, 43:2797-2809.
31. van Dissel J.T., Soonawala D., Joosten S.A., Prins C., Arend S.M., Bang P., et al. Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 2011, 29:2100-2109.
32. Pourcyrous M., Korones S.B., Arheart K.L., Bada H.S. Primary immunization of premature infants with gestational age <35 weeks: cardiorespiratory complications and C-reactive protein responses associated with administration of single and multiple separate vaccines simultaneously. J Pediatr 2007, 151:167-172.
33. + T cells in adults. Am J Respir Crit Care Med 2010, 181:1407-1417.
34. He H., Yang H., Deng Y. Mycobacterium tuberculosis dormancy-associated antigen of Rv2660c induces stronger immune response in latent Mycobacterium tuberculosis infection than that in active tuberculosis in a Chinese population. Eur J Clin Microbiol Infect Dis 2015, 34:1103-1109.
35. Gideon H.P., Wilkinson K.A., Rustad T.R., Oni T., Guio H., Sherman D.R., et al. Bioinformatic and empirical analysis of novel hypoxia-inducible targets of the human antituberculosis T cell response. J Immunol 2012, 189:5867-5876.
36. + T cells. PLOS ONE 2015, 10:e0122560.
37. Scriba T.J., Tameris M., Smit E., van der Merwe L., Hughes E.J., Kadira B., et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 2012, 185:769-778.
38. Day C.L., Tameris M., Mansoor N., van Rooyen M., de Kock M., Geldenhuys H., et al. Induction and regulation of t-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med 2013, 188:492-502.
39. + T lymphocytes with cellular maturation. J Exp Med 2006, 203:2865-2877.
40. Appay V., van Lier R.A., Sallusto F., Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008, 73:975-983.
41. + T cells following re-immunization. Eur J Immunol 2007, 37:1129-1138.
42. Aagaard C., Hoang T.T., Izzo A., Billeskov R., Troudt J., Arnett K., et al. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS ONE 2009, 4:e5930.
43. Soares A.P., Kwong Chung C.K., Choice T., Hughes E.J., Jacobs G., van Rensburg E.J., et al. Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns. J Infect Dis 2013, 207:1084-1094.
44. Soares A.P., Scriba T.J., Joseph S., Harbacheuski R., Murray R.A., Gelderbloem S.J., et al. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 2008, 180:3569-3577.
45. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763.